Atrás
Rango del Día
$62.95
$64.06
Rango de 52 Semanas
$32.48
$71.92
Volumen
647,446
Promedio 50D / 200D
$64.85
/
$55.98
Cierre Anterior
$62.19
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -14.3 | 0.4 |
| P/B | 2.9 | 2.9 |
| ROE % | -19.2 | 3.7 |
| Net Margin % | -17.5 | 3.9 |
| Rev Growth 5Y % | 7.6 | 10.0 |
| D/E | 0.4 | 0.2 |
Precio Objetivo de Analistas
Hold
$75.88
+20.0%
Low: $66.00
High: $85.00
P/E Futuro
15.0
EPS Futuro
$4.21
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
1.5 B
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2030 |
$6.41
$6.14 – $6.53
|
1.9 B | 1 |
| FY2029 |
$5.81
$5.57 – $5.92
|
1.8 B | 1 |
| FY2028 |
$5.05
$4.60 – $5.50
|
1.7 B | 2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 11, 2026 |
Poletti Franco
President, Cardiopulmonary
|
other | 6,329 | $57.60 | — |
| Dec 15, 2025 |
Poletti Franco
President, Cardiopulmonary
|
other | 2,350 | — | — |
| Dec 15, 2025 |
Hutchinson Michael Damon
SVP, CLO and Company Secretary
|
other | 5,630 | — | — |
| Dec 15, 2025 |
PODLOGAR SUSAN M
Director
|
other | 4,979 | — | — |
| Nov 18, 2025 |
Story Brooke
Director
|
sell | 250 | $53.94 | $13,485 |
| Sep 15, 2025 |
Poletti Franco
President, Cardiopulmonary
|
other | 1,563 | — | — |
| Aug 25, 2025 |
Bianchi Francesco
Director
|
sell | 1,500 | $56.50 | $84,750 |
| Jun 15, 2025 |
Story Brooke
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
Story Brooke
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
SCHERMERHORN TODD C
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
SCHERMERHORN TODD C
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
KOZY WILLIAM A
Director
|
other | 10,261 | — | — |
| Jun 15, 2025 |
KOZY WILLIAM A
Director
|
grant | 5,681 | — | — |
| Jun 15, 2025 |
PODLOGAR SUSAN M
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
Barry James Christopher
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
Barry James Christopher
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
Enxing Seng Stacy
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
Enxing Seng Stacy
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
Tezel Ahmet
Chief Innovation Officer
|
other | 6,966 | — | — |
| Jun 15, 2025 |
WILVER PETER M
Director
|
other | 7,242 | — | — |
Puntos Clave
Revenue grew 7.60% annually over 5 years — modest growth
Earnings declined -483.50% over the past year
Debt/Equity of 0.39 — conservative balance sheet
Generating 173.20M in free cash flow
PEG of 0.03 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.14%
Crecimiento
Revenue Growth (5Y)
7.60%
Revenue (1Y)10.74%
Earnings (1Y)-483.50%
FCF Growth (3Y)108.26%
Calidad
Return on Equity
-19.24%
ROIC8.94%
Net Margin-17.47%
Op. Margin14.36%
Seguridad
Debt / Equity
0.39
Current Ratio1.36
Interest Coverage4.04
Valoración
P/E Ratio
-14.26
P/B Ratio2.88
EV/EBITDA16.53
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.74% | Revenue Growth (3Y) | 9.70% |
| Earnings Growth (1Y) | -483.50% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 7.60% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1.39B | Net Income (TTM) | -242.50M |
| ROE | -19.24% | ROA | -9.31% |
| Gross Margin | 67.71% | Operating Margin | 14.36% |
| Net Margin | -17.47% | Free Cash Flow (TTM) | 173.20M |
| ROIC | 8.94% | FCF Growth (3Y) | 108.26% |
| Safety | |||
| Debt / Equity | 0.39 | Current Ratio | 1.36 |
| Interest Coverage | 4.04 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -14.26 | P/B Ratio | 2.88 |
| P/S Ratio | 2.49 | PEG Ratio | 0.03 |
| EV/EBITDA | 16.53 | Dividend Yield | 0.00% |
| Market Cap | 3.46B | Enterprise Value | 3.30B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.39B | 1.25B | 1.15B | 1.02B | 1.04B |
| Net Income | -242.50M | 63.23M | 17.55M | -86.25M | -135.82M |
| EPS (Diluted) | -4.45 | 1.16 | 0.32 | -1.61 | -2.68 |
| Gross Profit | 939.90M | 870.87M | 771.25M | 707.23M | 705.99M |
| Operating Income | 199.40M | 129.05M | -68.50M | -76.75M | -784,000.0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.61B | 2.51B | 2.43B | 2.29B | 2.20B |
| Total Liabilities | 1.41B | 1.19B | 1.15B | 1.09B | 906.31M |
| Shareholders' Equity | 1.20B | 1.32B | 1.28B | 1.21B | 1.29B |
| Total Debt | 473.30M | 676.77M | 640.40M | 580.43M | 286.70M |
| Cash & Equivalents | 635.60M | 428.86M | 266.50M | 214.17M | 207.99M |
| Current Assets | 1.10B | 1.13B | 988.16M | 886.14M | 679.18M |
| Current Liabilities | 808.10M | 392.13M | 334.98M | 297.40M | 696.97M |